Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.

Autor: Menne Z; Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA; Centers for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA., Pliasas VC; Centers for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, USA., Compans RW; Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA; Centers for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA., Glover S; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, USA., Kyriakis CS; Centers for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, USA., Skountzou I; Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA; Centers for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA. Electronic address: iskount@emory.edu.
Jazyk: angličtina
Zdroj: Virology [Virology] 2021 Oct; Vol. 562, pp. 197-208. Date of Electronic Publication: 2021 Aug 05.
DOI: 10.1016/j.virol.2021.08.001
Abstrakt: Neuraminidase (NA) is the second most abundant glycoprotein on the surface of influenza A viruses (IAV). Neuraminidase type 1 (NA1) based virus-like particles (VLPs) have previously been shown to protect against challenge with H1N1 and H3N2 IAV. In this study, we produced neuraminidase type 2 (NA2) VLPs derived from the sequence of the seasonal IAV A/Perth/16/2009. Intramuscular vaccination of mice with NA2 VLPs induced high anti-NA serum IgG levels capable of inhibiting NA activity. NA2 VLP vaccination protected against mortality in a lethal A/Hong Kong/1/1968 (H3N2) virus challenge model, but not against lethal challenge with A/California/04/2009 (H1N1) virus. However, bivalent vaccination with NA1 and NA2 VLPs demonstrated no antigenic competition in anti-NA IgG responses and protected against lethal challenge with H1N1 and H3N2 viruses. Here we demonstrate that vaccination with NA VLPs is protective against influenza challenge and supports focusing on anti-NA responses in the development of future vaccination strategies.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: